verteporfin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
verteporfin: clinical details
Prescribing considerations
- Restrict administration to ophthalmologists experienced in managing the licensed retinal conditions and photodynamic therapy.
- Confirm lesion type, location and dimensions using appropriate retinal imaging before treatment.
- Counsel about bright-light avoidance, protective clothing, sunglasses and the limitations of sunscreen.
- Establish and monitor a free-flowing intravenous line because extravasation can cause severe local injury.
- Review liver disease, biliary obstruction, pregnancy, breastfeeding, cardiovascular history, interacting photosensitisers and planned anaesthesia.
Contraindications and cautions
- Hypersensitivity to verteporfin or any excipient
- Porphyria
- Severe hepatic impairment
Monitoring
- Monitor continuously for infusion reactions, hypersensitivity, haemodynamic changes and extravasation.
- Assess visual acuity and retinal findings before and after treatment; marked early visual deterioration requires specialist reassessment.
- Protect any extravasation site from bright light until swelling and discolouration resolve.
- Use particular caution in moderate hepatic dysfunction or biliary obstruction; renal-impairment evidence is limited.
Clinical pharmacology
Verteporfin is a light-activated benzoporphyrin photosensitiser. Activation in oxygenated tissue generates singlet oxygen, producing local endothelial injury and vascular occlusion. It is highly plasma-protein associated, undergoes limited esterase hydrolysis and is eliminated predominantly through the biliary route.
Formulation and product differences
- The selected product is a dark green to black powder requiring reconstitution and further dilution before intravenous infusion.
- Use water for reconstitution and glucose infusion solution for dilution; verteporfin precipitates in sodium chloride solutions.
- The vial is single use and must be protected from light. The formulation contains egg phosphatidylglycerol and butylated hydroxytoluene (E321).
verteporfin preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 15 mg
verteporfin interactions
Formal human interaction studies are unavailable. Give the eye team a complete list of medicines, supplements and current radiotherapy.
Photosensitising medicines, including tetracyclines, sulphonamides, phenothiazines, sulfonylureas, thiazide diuretics and griseofulvin
May increase the likelihood or severity of photosensitivity reactions.
Calcium-channel blockers, polymyxin B and radiotherapy
Could theoretically increase verteporfin uptake into vascular tissue, although clinical evidence is lacking.
Antioxidants and free-radical scavengers, including beta-carotene, mannitol and dimethyl sulfoxide
Could theoretically reduce verteporfin activity by neutralising the reactive oxygen species it generates.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.